FOLH1 and prostate carcinoma: In vitro and in vivo studies of [99mTc]Tc-EDDA-HYNIC-iPSMA, rapidly prepared from a kit formulation with a radiochemical yield exceeding 95%, demonstrating that this radiopharmaceutical could detect tumors and metastases of prostate cancer (PCa) similar to [68Ga]Ga-PSMA-617 (Ferro-Flores et al. 2017).